BWAY News

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025